Recently, the ACRG used primary gastrectomy samples to characterize 4 subtypes of GC linked to distinct patterns of molecular alterations and prognosis: MSI-H tumors (22.7%), which have the best prognosis; microsatellite stable (MSS)/epithelial to mesenchymal transition (EMT) tumors (15.3%), characterized by loss of CDH1 and worst prognosis; and MSS/TP53 active (26.3%) and inactive (35.7%) tumors, both of which have an intermediate prognosis [12]. Here, TP53 is linked to gastric cancer.